Special Purpose Acquisition Companies (SPACs) have built-in dilution mechanisms that many retail investors don't fully understand when they buy in. The "SPAC discount" that institutional arbitrageurs apply to SPAC shares reflects these dilution factors. Understanding them in advance lets you price SPAC investments more accurately.
A SPAC IPOs at $10/share, placing proceeds in trust. The SPAC sponsor receives "founder shares" (typically 20% of the initial offering) for minimal consideration. The SPAC has 18–24 months to complete a merger with a private target. When the merger closes (the "de-SPAC"), public shareholders can redeem their shares at trust value (~$10) or keep them as shares in the combined company.
SPAC sponsors receive 20% of the post-IPO shares outstanding for essentially nothing (often $25,000 total). This "promote" is worth tens or hundreds of millions of dollars in a successful SPAC. For public shareholders, this means they entered a vehicle where 20% of the equity was already given away before the business combination closed.
Example: A $200M SPAC IPO creates 20M public shares. The sponsor receives 5M founder shares (20% = 5M/25M total). Those founder shares were purchased for $25,000 but are worth ~$50M at $10/share. This 20% dilution exists from day one.
Most SPACs issue warrants as part of their IPO units. These warrants typically allow holders to purchase one share at $11.50 per share, exercisable after the de-SPAC closes. If the combined company's stock trades above $11.50, warrant holders will exercise — creating new shares and diluting existing shareholders.
The number of warrants outstanding versus shares outstanding (the "warrant coverage ratio") is a key metric. A SPAC with 20M shares and 10M outstanding warrants has 50% warrant coverage — if all warrants exercise, shares outstanding increase by 50%.
Beyond public warrants, sponsors also receive private placement warrants as part of their compensation. These warrants have similar terms to public warrants but are not initially tradeable. They create additional dilution upon exercise and are disclosed in the SPAC's S-1 registration statement and subsequent proxy statements (DEFM14A).
When a SPAC announces a merger target, it typically simultaneously announces a PIPE (Private Investment in Public Equity) — a private placement of shares to institutional investors to supplement the trust proceeds. PIPE investors often receive shares at $10 with warrants attached, at pricing that may be more favorable than public shareholders receive.
The PIPE is essential for closing most de-SPAC transactions (because redemptions often reduce available trust cash), but it adds another layer of dilution on top of the existing warrant and founder share overhang.
At the time of the de-SPAC vote, public shareholders can redeem their shares for trust value (~$10). In many recent SPACs, redemption rates have been 80–95%+ — meaning most public shareholders take their money back rather than holding equity in the combined company. This creates a paradox:
When 90%+ of shares redeem, the surviving public shareholders are primarily PIPE investors and retail buyers who didn't redeem. The sponsor still has their full founder share allocation. The company has far less cash than the trust suggested. This creates a near-certain need for post-merger dilutive financing — typically within 6–18 months of merger close.
To estimate total SPAC dilution, add up:
It's common for total potential dilution from all these sources to equal 30–60% of the SPAC's initial share count. This is why institutional SPAC arbitrageurs demand discounts to trust value and why post-merger SPAC stocks often underperform.
After the de-SPAC merger closes, the company transitions to a regular SEC reporting schedule. From that point, treat it like any other small-cap for dilution monitoring:
DilutionWatch monitors post-de-SPAC companies for dilution risk including warrant overhang, cash runway, and new offering activity. Includes DilutionScore™ tracking and real-time alerts.
Start Free Monitoring →